Corporate News
Director/PDMR Shareholding
27 January 2023
Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that on 26 January 2023 it received notification that Jag Grewal, Chief Executive Officer, and Chris Lea, Chief Financial Officer, had each purchased 1,000,000 ordinary shares of 4 pence each in the Company (“Ordinary Shares”), at a price of 3.4839 pence each.
A summary of each Directors resultant holdings is below:
| Director | Board Position | Existing number of Ordinary Shares | Ordinary Shares Purchased | Total beneficial holding of Ordinary Shares following these acquisitions | |
|---|---|---|---|---|---|
| Number of Ordinary Shares | Approximate % of Company’s issued share capital | ||||
| Jag Grewal | CEO | 1,025,834 | 1,000,000 | 2,025,834 | 0.85% |
| Chris Lea | CFO | 1,030,908 | 1,000,000 | 2,030,908 | 0.85% |
Contacts:
| Omega Diagnostics Group PLC | www.omegadx.com |
| Jag Grewal Chief Executive Officer | via Walbrook PR |
| Chris Lea, Chief Financial Officer | |
| finnCap Ltd | Tel: 020 7220 0500 |
| Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance) | |
| Alice Lane/ Charlotte Sutcliffe (ECM) | |
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] |
| Paul McManus | Mob: 07980 541 893 |
| Lianne Applegarth | Mob: 07584 391 303 |
| Sam Allen | Mob: 07502 558 258 |
About Omega Diagnostics Group PLC
Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.
www.omegadx.com
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) |
Name | Jag Grewal | ||||
| 2 | Reason for the notification | |||||
| a) |
Position/status | Chief Executive Officer | ||||
| b) |
Initial | Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) |
Name | Omega Diagnostics Group PLC | ||||
| b) | LEI | 2138007U9P4BTZTYIR92 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 4 pence each ISIN: GB00B1VCP282 | ||||
| b) | Nature of the transaction | Ordinary Shares purchased | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information -Aggregated volume | See above | ||||
| - Price | ||||||
| e) | Date of the transaction | 26.01.2023 | ||||
| f) | Place of the transaction | London Stock Exchange | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) |
Name | Chris Lea | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Financial Officer | ||||
| b) | Initial notification /Amendment | Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) |
Name | Omega Diagnostics Group PLC | ||||
| b) | LEI | 2138007U9P4BTZTYIR92 | ||||
| 4 | Details of the tra nsaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 4 pence each ISIN: GB00B1VCP282 | ||||
| b) | Nature of the transaction | Ordinary Shares purchased | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information -Aggregated volume - Price | See above | ||||
| e) | Date of the transaction | 26.01.2023 | ||||
| f) | Place of the transaction | London Stock Exchange | ||||
